Editing Cystic fibrosis (section)

===Bacteriophage therapy===
Bacteriophage therapy ([[phage therapy]]) is being studied for multidrug-resistant bacteria in people with CF.<ref name="pmid26213462">{{cite journal | vauthors = Hraiech S, Brégeon F, Rolain JM | title = Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status | journal = Drug Design, Development and Therapy | volume = 9 | pages = 3653–3663 | date = 2015 | pmid = 26213462 | pmc = 4509528 | doi = 10.2147/DDDT.S53123 | doi-access = free }}</ref><ref name="pmid28720345">{{cite journal | vauthors = Trend S, Fonceca AM, Ditcham WG, Kicic A, Cf A | title = The potential of phage therapy in cystic fibrosis: Essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways | journal = Journal of Cystic Fibrosis | volume = 16 | issue = 6 | pages = 663–670 | date = November 2017 | pmid = 28720345 | doi = 10.1016/j.jcf.2017.06.012 | doi-access = free }}</ref> Bacteriophage therapy is a treatment method that uses viruses, known as [[bacteriophage]]s, to target and destroy harmful bacteria in the body. Unlike antibiotics, which can kill a wide range of bacteria and potentially disrupt the body's normal flora, phage therapy is highly specific, targeting only the harmful bacteria while leaving the beneficial ones unharmed. As such, bacteriophage therapy is a promising alternative for treating infections caused by multidrug-resistant bacteria, such as Staphylococcus aureus, Haemophilus influenzae, and Pseudomonas aeruginosa in CF patients, which are often protected by biofilms and thus resistant to conventional antibiotics.<ref name="a">{{cite journal | vauthors = Petrovic Fabijan A, Iredell J, Danis-Wlodarczyk K, Kebriaei R, Abedon ST | title = Translating phage therapy into the clinic: Recent accomplishments but continuing challenges | journal = PLOS Biology | volume = 21 | issue = 5 | pages = e3002119 | date = May 2023 | pmid = 37220114 | doi = 10.1371/journal.pbio.3002119 | doi-access = free | pmc = 10204993 }}</ref><ref name="b">{{cite journal | vauthors = Ashworth EA, Wright RC, Shears RK, Wong JK, Hassan A, Hall JP, Kadioglu A, Fothergill JL | title = Exploiting lung adaptation and phage steering to clear pan-resistant Pseudomonas aeruginosa infections in vivo | journal = Nature Communications | volume = 15 | issue = 1 | pages = 1547 | date = February 2024 | pmid = 38378698 | doi = 10.1038/s41467-024-45785-z | pmc = 10879199 | bibcode = 2024NatCo..15.1547A }}</ref><ref name="c">{{cite journal | vauthors = Liu K, Wang C, Zhou X, Guo X, Yang Y, Liu W, Zhao R, Song H | title = Bacteriophage therapy for drug-resistant <i>Staphylococcus aureus</i> infections | journal = Frontiers in Cellular and Infection Microbiology | volume = 14 | pages = 1336821 | date = 31 January 2024 | pmid = 38357445 | doi = 10.3389/fcimb.2024.1336821 | doi-access = free | pmc = 10864608 }}</ref>

Bacteriophage therapy uses viruses as antimicrobial agents to overcome the antibiotic resistance in bacteria with biofilms<ref name="pmid17566713">{{cite journal | vauthors = Hanlon GW | title = Bacteriophages: an appraisal of their role in the treatment of bacterial infections | journal = International Journal of Antimicrobial Agents | volume = 30 | issue = 2 | pages = 118–128 | date = August 2007 | pmid = 17566713 | doi = 10.1016/j.ijantimicag.2007.04.006 }}</ref> Phage therapy is used to treat the [[Pseudomonas aeruginosa]] infection in the lungs, which is frequently seen in cystic fibrosis patients, as these bacteria produce biofilms which give them multi-drug resistance.<ref name="pmid31130925">{{cite journal | vauthors = Ciofu O, Tolker-Nielsen T | title = Tolerance and Resistance of <i>Pseudomonas aeruginosa</i> Biofilms to Antimicrobial Agents-How <i>P. aeruginosa</i> Can Escape Antibiotics | journal = Frontiers in Microbiology | volume = 10 | pages = 913 | date = 2019 | pmid = 31130925 | pmc = 6509751 | doi = 10.3389/fmicb.2019.00913 | doi-access = free }}</ref>